Stockscreener 앱 받기
6.50
2.11%
-0.14
Adicet Bio Inc 주식(ACET)의 최신 뉴스
A new hire waits a year to gain the right to buy Adicet shares - Stock Titan
Adicet Bio, Inc. (ACET) Discusses Positive Prula-cel Data and Plans for Pivotal Study in Lupus NephritisSlideshow - Seeking Alpha
H.C. Wainwright Maintains Adicet Bio(ACET.US) With Buy Rating, Raises Target Price to $34 - Moomoo
H.C. Wainwright raises Adicet Bio stock price target on lupus data By Investing.com - Investing.com South Africa
H.C. Wainwright raises Adicet Bio stock price target on lupus data - Investing.com Nigeria
Several high-volume stocks plunge sharply amid profit-taking despite positive updates. - Pluang
An ‘off-the-shelf’ CAR-T therapy from Adicet shows promise against lupus - BioPharma Dive
Wedbush raises Adicet Bio stock price target on lupus trial data - Investing.com
Adicet Bio Reports Positive Prula-cel Phase 1 Lupus Data as Pivotal Study Plans Advance - Yahoo Finance
Adicet Bio (NASDAQ:ACET) Stock Gets Price Target Boost from HC Wainwright - MarketBeat
HC Wainwright & Co. maintains Buy rating on Adicet Bio, $34 price target - TradingView
Adicet Bio Reports Phase 1 Prula-cel Data in Lupus Patients - Yahoo Finance
Adicet Bio reports lupus trial results, plans pivotal study By Investing.com - Investing.com Nigeria
Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis - The Daily Tribune News
Adicet Bio (NASDAQ:ACET) Earns Buy Rating from HC Wainwright - MarketBeat
Adicet Bio (NASDAQ:ACET) Shares Break Above 200-Day Moving AverageShould You Sell? - MarketBeat
Adicet Bio (NASDAQ:ACET) Stock Moved Up to "Hold" by Wall Street Zen - MarketBeat
Data on a possible lupus treatment are due Monday - Stock Titan
H.C. Wainwright reiterates Adicet Bio stock rating on data update By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Adicet Bio stock rating on data update - Investing.com
HC Wainwright & Co. reiterates Buy rating on Adicet Bio, $27 price target - TradingView
Adicet Bio, Inc. (NASDAQ:ACET) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Adicet Bio (ACET): The Countdown To Prula-cel Data - RTTNews
Adicet Bio (NASDAQ:ACET) Stock Passes Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Adicet Bio Highlights Prula-cel Autoimmune CAR-T Pipeline Progress - TipRanks
Adicet Bio posts September 2026 investor presentation outlining prula-cel and ADI-212 clinical timelines - TradingView
Adicet Bio Stock Price Forecast. Should You Buy ACET? - StockInvest.us
Wall Street Analysts See a 258.21% Upside in Adicet Bio (ACET): Can the Stock Really Move This High? - Yahoo Finance
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Adicet Bio (NASDAQ:ACET) Upgraded to Strong-Buy at Jefferies Financial Group - marketbeat.com
A biotech CEO will speak in New York Sept. 15. Audio will be online. - Stock Titan
Adicet Bio to Participate in Fireside Chat at H.C. Wainwright 28th Annual Global Investment Conference - Lelezard
Adicet Bio (NASDAQ: ACET) Advances ADI-212 Clinical Trial for mCRPC and Prepares Prula-Cel Data Release - Kalkine Media
Adicet Bio (NASDAQ: ACET) Advances ADI-212 Clinical Trial for mCRPC, Prula-cel Data Expected in September 2026 - Kalkine Media
Adicet Bio, Inc. (NASDAQ:ACET) Sees Large Drop in Short Interest - MarketBeat
Adicet Bio advances CAR-T programs and clinical pipeline - grafa.com
Adicet Bio completes prula-cel Phase 1 SLE analysis - TipRanks
Adicet Bio says prula-cel last patient visit complete; topline data due Sept 2026, ADI-212 IND cleared - TradingView
The final patient visit is complete in a lupus cell-therapy study. Adicet Bio expects results from 22 patients in September. - stocktitan.net
Adicet Bio grants a new hire options on 1,500 shares over four years - Stock Titan
ACET Q2 2026 Earnings: Narrower Loss Beats Expectations as Pipeline AdvancesEarnings Cycle Outlook - dars.gov.et
Press Release Service: Adicet Bio Announces FDA Clearance of IND Application for ADI-212 - CRISPR Medicine News
Adicet Bio Gets FDA Clearance for IND for ADI-212 in prostate cancer - marketscreener.com
Adicet Bio receives FDA clearance for prostate cancer trial By Investing.com - Investing.com Canada
Adicet Bio receives FDA clearance for prostate cancer trial - Investing.com India
Zacks Investment Research - גלובס
Adicet (ACET) Trading: Adds 0.32% to Close at $9.41 in the Current Update; Key Range - vinanet.vn
ETFs Investing in Adicet Bio Inc Stocks - TradingView
Are Medical Stocks Lagging Adicet Bio (ACET) This Year? - Eastern Progress
ACET Q2 2026 Earnings: Narrower-Than-Expected Loss of $1.99 Per Share Buoys SharesSegment Revenue Breakdown - vinanet.vn
RA Capital discloses 9.99% Adicet Bio (ACET) stake with warrant blocker - Stock Titan
Adicet Bio (ACET) - Zacks Investment Research
Adicet Bio: A Cheap Gamma Delta T-Cell Play (NASDAQ:ACET) - Seeking Alpha
Wall Street Analysts Think Adicet Bio (ACET) Could Surge 301.57%: Read This Before Placing a Bet - Zacks Investment Research
Adicet Bio (ACET) Edges Higher to $8.26 as Biotech Stock Consolidates Between Key LevelsETF Flow - Vinanet
HC Wainwright Has Strong Estimate for Adicet Bio Q3 Earnings - MarketBeat
Adicet Bio at Canaccord Genuity: lupus data drives next step By Investing.com - Investing.com Canada
Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell Therapy - MarketBeat
0.05%
0.82%
자본화:
|
볼륨(24시간):